3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Lung Cancer Metastatic
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
347
pembrolizumab
322
Pemetrexed
246
Cisplatin
218
Paclitaxel
147
Nivolumab
138
durvalumab
133
osimertinib
112
Docetaxel
111
atezolizumab
109
Specimen Handling
91
Radiotherapy
87
Drug Therapy
85
Magnetic Resonance Spectroscopy
77
Etoposide
76
Radiosurgery
72
Gemcitabine
71
Ipilimumab
55
130-nm albumin-bound paclitaxel
54
Bevacizumab
52
cemiplimab
47
tislelizumab
44
Blood Specimen Collection
40
Cetuximab
35
Taxes
34
Platinum
33
Injections
33
Biopsy
33
Standard of Care
31
Immunoglobulin G
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
evolocumab
×
Thoracic
×
1 year
×
Clear all
NCT03337698
2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2
Terminated
314 enrolled
31 charts
NCT05144529
2026-05-05
TOP2101
Duke University
Phase 2
Terminated
19 enrolled
16 charts